Cancer Family
Benign Epithelial Neoplasm
CI-CAN-00000077Explore in graph →
Non-malignant30 active trials
- NCIt
- C4092
Loading cancer entity…
Cancer Family
CI-CAN-00000077Explore in graph →
Clinical trials
161 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03194906 | Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors | completed | Phase 2 | 41 | St. Jude Children's Research HospitalOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06054178 | Identification of Nerves Using Fluorescein Sodium | completed | Phase 2 | 8 | Stanford UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05799157 | Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts | completed | Phase 2 | 153 | Veradermics, Inc.INDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT01767636 | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 38 | Mayo ClinicOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT03487549 | Cantharidin and Occlusion in Verruca Epithelium(COVE-1) | completed | Phase 2 | 56 | Verrica Pharmaceuticals Inc.INDUSTRY | 1 | Nov 27, 2024 | clinicaltrials |
| NCT05896215 | OM202JP Clinical Study of KNP2002 | completed | Phase 2 | 159 | KinoPharma Inc.INDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT05877313 | Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts) | completed | Phase 2 | 20 | Sanotize Research and Development corp.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT02842723 | Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy (Craniopharyngioma) | completed | Phase 2 | 33 | Institut CurieOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT02849743 | Intranasal Oxytocin in Hypothalamic Obesity | completed | Phase 2 | 18 | Shana McCormack, MDOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT02468193 | Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome | completed | Phase 2 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | May 6, 2020 | clinicaltrials |
| NCT03210337 | A Phase2 of A-101 Topical Solution in Subjects With Common Warts | completed | Phase 2 | 157 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | May 1, 2019 | clinicaltrials |
| NCT03278028 | A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts | completed | Phase 2 | 159 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | Apr 9, 2019 | clinicaltrials |
| NCT01484873 | Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor | completed | Phase 2 | 10 | Vanderbilt University Medical CenterOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT02150213 | Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 5, 2016 | clinicaltrials |
| NCT02063295 | An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury | completed | Phase 2 | 14 | Zafgen, Inc.INDUSTRY | 2 | Jul 18, 2016 | clinicaltrials |
| NCT02483455 | ALC-919 For The Treatment Of Common Warts | completed | Phase 2 | 21 | Veloce BioPharma LLCINDUSTRY | 1 | Mar 9, 2016 | clinicaltrials |
| NCT00004078 | Irinotecan in Treating Children With Refractory Solid Tumors | completed | Phase 2 | 181 | Children's Oncology GroupNETWORK | 1 | Jun 14, 2013 | clinicaltrials |
| NCT01214564 | Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis | completed | Phase 2 | 24 | PeplinINDUSTRY | 1 | Jan 25, 2011 | clinicaltrials |
| NCT00038714 | A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis | completed | Phase 2 | 27 | Nventa Biopharmaceuticals CorporationINDUSTRY | 1 | Jun 27, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Jun 23, 2026source: clinicaltrials